Marina's drug for colon polyps gets FDA's orphan-drug status

12/29/2010 | American City Business Journals

The FDA granted orphan-drug designation to CEQ508, Marina Biotech's lead compound for familial adenomatous polyposis. The status "provides us with significant regulatory and financial incentives to do everything in our power to rapidly move this compound to market," said CEO and President J. Michael French.

View Full Article in:

American City Business Journals

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Regional Director, Southeastern Region - State Affairs
America's Health Insurance Plans (AHIP)
Washington, DC
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)
Multiple Locations, SL_Multiple Locations
Market Intelligence Manager
Olympus Corporation of the Americas
Southborough, MA